NCT01582503
Completed
Phase 2
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Dosing Regimens of MEMP1972A in Adults With Allergic Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids and a Second Controller (COSTA)
Overview
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Genentech, Inc.
- Enrollment
- 578
- Primary Endpoint
- Rate of protocol-defined asthma exacerbations (new or increased asthma symptoms that lead to treatment with systemic corticosteroids or to hospitalization) from baseline to Week 36
Overview
Brief Summary
This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients, 18 to 75 years of age inclusive
- •Body weight \>/= 40 kg
- •Physician's diagnosis of asthma for at least 12 months
- •Evidence of documented bronchodilator reversibility as defined by protocol
- •Prebronchodilator FEV1 \>/= 40% and \</= 80% predicted at Visit 1
- •Required daily use of ICS and a second controller for a minimum of 3 consecutive months prior to Visit 1
- •History of at least one protocol-defined asthma exacerbation in the 18 months prior to Visit 1
- •Inadequately controlled asthma despite compliance with asthma controller therapy
Exclusion Criteria
- •Asthma exacerbation requiring systemic steroids in the 30 days prior to Visit 1
- •Pre-existing active lung disease other than asthma
- •Any infection
- •Clinically significant medical disease that is uncontrolled despite treatment or is likely to require a change in therapy during study or is of unknown etiology
- •Known immunodeficiency, including but not limited to HIV infection, regardless of treatment status
- •Current substance abuse
- •Former smoker with \>10 pack-year history or current smoker; former smokers must have stopped smoking more than 12 months prior to Visit 1
- •History of anaphylaxis
- •Pregnant and lactating women
Arms & Interventions
MEMP1972A 450 mg
Experimental
Intervention: MEMP1972A (Drug)
Placebo
Placebo Comparator
Intervention: placebo (Drug)
MEMP1972A 300 mg
Experimental
Intervention: MEMP1972A (Drug)
MEMP1972A 150 mg
Experimental
Intervention: MEMP1972A (Drug)
Outcomes
Primary Outcomes
Rate of protocol-defined asthma exacerbations (new or increased asthma symptoms that lead to treatment with systemic corticosteroids or to hospitalization) from baseline to Week 36
Time Frame: 36 weeks
Secondary Outcomes
- Relative change in pre-bronchodilator FEV1 (volume)(from baseline to Week 12)
- Relative change in FEV1 (volume)(from baseline to Week 36)
- Change in asthma symptoms(from baseline to Week 36)
- Proportion of "well-controlled" weeks (no nighttime awakenings due to asthma symptoms and </= 2 days of SABA use per weeks, as documented by patient diary) from Week 24 to Week 36(12 weeks)
- Safety: Incidence of adverse events(48 weeks)
- Incidence of anti-therapeutic antibodies (ATAs)(84 weeks)
- Pharmacokinetics: Area under the concentration-time curve (AUC)(Pre- and post-dose Weeks 0, 4, 12, 24 and 36)
Investigators
Similar Trials
Completed
Phase 3
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)Herpes ZosterNCT01229267Merck Sharp & Dohme LLC1,257
Recruiting
Phase 2
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19Mild to Moderate COVID-19NCT05675072Frontier Biotechnologies Inc.1,336
Recruiting
Phase 2
Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)COVID-19NCT05445934Frontier Biotechnologies Inc.1,188
Completed
Phase 2
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)Coronavirus Disease 2019 COVID-19NCT04341116I-Mab Biopharma US Limited149
Completed
Phase 3
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopaParkinson DiseaseNCT00381472GlaxoSmithKline393